Navigation Links
Halozyme Therapeutics Announces Public Offering of Common Stock
Date:9/8/2010

y from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.Halozyme Contact  Robert H. UhlSenior Director, Investor Relations(858) 704-8264ruhl@halozyme.com
'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
(Date:12/19/2014)... Dec. 18, 2014 Baptist Health Lexington is the ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation ... Atrial fibrillation is the most common cardiac arrhythmia and ... cases can lead to stroke and possible death. More than ... have atrial fibrillation and the numbers are rapidly increasing ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... 2014 Xarelto bleeding lawsuits filed ... uncontrollable bleeding and other serious side effects will be ... Louisiana for coordinated pretrial proceedings, Wright & Schulte LLC ... issued an order Friday to transfer 21 Xarelto lawsuits ... federal courts to the Louisiana district court for coordination ...
(Date:12/19/2014)... 20, 2014 Today, Balfleet.com , ... outfits, announces its formal dress promotion. All the old ... to 60% off. , Balfleet.com is well-known for its ... dresses, prom dresses, cocktail dresses and more. Its formal ... money-back guarantee, and they can create an elegant look ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... TAMPA, Fla. -- Alexander R. A. Anderson, Ph.D., co-director ... and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University ... have received a five-year, $3 million grant from the ... to predict prostate cancer aggressiveness. "Mathematical models have ...
... HealthDay Reporter , THURSDAY, Oct. 20 (HealthDay News) -- The ... worry about an increased risk of brain cancer, new Danish research ... subject finds no more brain tumors among people who had cell ... phones. Although no one study can rule out harm with ...
... HealthDay Reporter , FRIDAY, Oct. 21 (HealthDay News) ... hormone production as the testes and adrenal glands. But those ... new study, showing hormone production in the penis itself, turn ... in both mice and human tissue, revealing that proteins key ...
... new development paths towards a healthier life. New opportunities ... development, industrial biotechnology and environmental technology have been a ... , VTT is one of the organisers of Metabomeeting ... at the end of September. Professor Jeremy K. Nicholson ...
... scientists advances a strategy for taming the side effects ... medications that work by disrupting the activity of certain ... developed at St. Jude. In this study, scientists showed ... activity of genes in a cell signaling pathway regulated ...
... over the years has made it possible for researchers and ... using ionising radiation, for example X-rays. The images ... of water in the body, since the body is largely ... nuclei in water molecules. It can also be used to ...
Cached Medicine News:Health News:Researchers get $3 million National Institutes of Health grant for mathematical models of prostate cancer aggressiveness 2Health News:Cell Phones Don't Raise Brain Cancer Risk, Study Says 2Health News:Cell Phones Don't Raise Brain Cancer Risk, Study Says 3Health News:Research Suggests Penis Might Produce Testosterone 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 3Health News:New instrument helps researchers see how diseases start and develop in minute detail 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: